These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 11238235)

  • 21. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.
    Holguín A; Paxinos E; Hertogs K; Womac C; Soriano V
    J Clin Virol; 2004 Nov; 31(3):215-20. PubMed ID: 15465415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel and efficient approach to discriminate between pre- and post-transcription HIV inhibitors.
    Daelemans D; Pannecouque C; Pavlakis GN; Tabarrini O; De Clercq E
    Mol Pharmacol; 2005 May; 67(5):1574-80. PubMed ID: 15728798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance.
    de Mendoza C; Garrido C; Corral A; Zahonero N; Soriano V
    AIDS; 2008 Jan; 22(2):311-3. PubMed ID: 18097236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thermodynamic rules for the design of high affinity HIV-1 protease inhibitors with adaptability to mutations and high selectivity towards unwanted targets.
    Ohtaka H; Muzammil S; Schön A; Velazquez-Campoy A; Vega S; Freire E
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1787-99. PubMed ID: 15183345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
    Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
    J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to protease inhibitors.
    Kuritzkes DR
    J HIV Ther; 2002 Nov; 7(4):87-91. PubMed ID: 12733606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. No inherent association between minor mutations in HIV protease at baseline and selection of the L90M mutation at the time of the first virological failure.
    Brumme CJ; Harrigan PR
    J Infect Dis; 2005 May; 191(10):1778-9; author reply 1779-80. PubMed ID: 15838807
    [No Abstract]   [Full Text] [Related]  

  • 29. Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors.
    Menzo S; Monachetti A; Balotta C; Corvasce S; Rusconi S; Paolucci S; Baldanti F; Bagnarelli P; Clementi M
    AIDS; 2003 Mar; 17(5):663-71. PubMed ID: 12646788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach.
    Jenwitheesuk E; Samudrala R
    Antivir Ther; 2005; 10(1):157-66. PubMed ID: 15751773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.
    Nakatani S; Hidaka K; Ami E; Nakahara K; Sato A; Nguyen JT; Hamada Y; Hori Y; Ohnishi N; Nagai A; Kimura T; Hayashi Y; Kiso Y
    J Med Chem; 2008 May; 51(10):2992-3004. PubMed ID: 18426195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence for preferential genotyping of a minority human immunodeficiency virus population due to primer-template mismatching during PCR-based amplification.
    Martinez-Picado J; Morales-Lopetegi K; Villena C; Gutiérrez C; Izquierdo N; Marfil S; Clotet B; Ruiz L
    J Clin Microbiol; 2005 Jan; 43(1):436-8. PubMed ID: 15635008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of virologic response to ritonavir-boosted protease inhibitors.
    Marcelin AG; Flandre P; Peytavin G; Calvez V
    AIDS Rev; 2005; 7(4):225-32. PubMed ID: 16425962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymorphisms in HIV-1 subtype C proteases and the potential impact on protease inhibitors.
    Bessong PO
    Trop Med Int Health; 2008 Feb; 13(2):144-51. PubMed ID: 18304259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Among the devils in the details are protease sequence, susceptibility, and structure in CRF02_AG viruses.
    Katzenstein D; Ogden R
    Clin Infect Dis; 2005 Jul; 41(2):252-4. PubMed ID: 15983924
    [No Abstract]   [Full Text] [Related]  

  • 36. Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive patients naïve for anti-retrovirals.
    Torti C; Bono L; Gargiulo F; Uccelli MC; Quiros-Roldan E; Patroni A; Paraninfo G; Tirelli V; Manca N; De Francesco MA; Perandin F; Carosi G
    Clin Microbiol Infect; 2004 Sep; 10(9):826-30. PubMed ID: 15355414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro synthesis of enzymatically active HIV-1 protease for rapid phenotypic resistance profiling.
    Hoffmann D; Buchberger B; Nemetz C
    J Clin Virol; 2005 Apr; 32(4):294-9. PubMed ID: 15780808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation.
    Lam E; Parkin NT
    Clin Infect Dis; 2003 Nov; 37(9):1273-4. PubMed ID: 14557976
    [No Abstract]   [Full Text] [Related]  

  • 39. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S; Ross P; Freire E
    Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism.
    Calazans A; Brindeiro R; Brindeiro P; Verli H; Arruda MB; Gonzalez LM; Guimaraes JA; Diaz RS; Antunes OA; Tanuri A
    J Infect Dis; 2005 Jun; 191(11):1961-70. PubMed ID: 15871131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.